CORPORATE PROFILE
• VJTBio is an animal healthcare company that integrates the discovery, development, production, and sale of innovative drugs.
• The company is committed to developing recombinant proteins and antibodies for veterinary uses, with a portfolio of pipelines that cover three core areas of livestock reproduction, disease prevention and control, and companion animal diseases.
• Most of our innovative drugs are classified as National Class I New Veterinary Drugs in China, many of which received PCT patents and are recognized as first-in-class globally.
• The company is committed to developing recombinant proteins and antibodies for veterinary uses, with a portfolio of pipelines that cover three core areas of livestock reproduction, disease prevention and control, and companion animal diseases.
• Most of our innovative drugs are classified as National Class I New Veterinary Drugs in China, many of which received PCT patents and are recognized as first-in-class globally.
MISSION
For animals, For humanity;
With reverence, devoted to making medicines.
With reverence, devoted to making medicines.
VISIONTo become a global leader in innovative animal drugs.
VALUECommitted to People's Well-being, Rooted in Dedication.
Integrity, Diligence, Focus, Innovation.
Integrity, Diligence, Focus, Innovation.
MISSION
For animals, For humanity;
With reverence, devoted to making medicines.
With reverence, devoted to making medicines.
VISIONTo become a global leader in innovative animal drugs.
VALUECommitted to People's Well-being, Rooted in Dedication.
Integrity, Diligence, Focus, Innovation.
Integrity, Diligence, Focus, Innovation.
CORE COMPETITIVENESS AND ADVANTAGES
01
High-efficiency protein drugs expression system based on mammalian cell.
02
Well-established antibody designing and screening platform.
03
Standarized pilot production, registration, and industrialization system.
04
Innovative pipelines and drug design.
MANUFACTURING SITE
VJTBio's manufacturing site in Zhejiang houses China's first GMP production line for animal recombinant protein and antibody drugs. This facility spans 10，000 square meters, with GMP production suites utilizing single-use production platforms.
FOUNDING TEAM
HONORS
Explore the prestigious honors and industry accolades VJTBio has received for our innovative research, pioneering treatments, and commitment to global health. Celebrate our achievements and milestones that drive us forward in transforming patient care.
Explore the prestigious honors and industry accolades VJTBio has received for our innovative research, pioneering treatments, and commitment to global health. Celebrate our achievements and milestones that drive us forward in transforming patient care.
GLOBAL MARKETING
As a leading Chinese animal health company, we are excited to announce our strategic initiatives aimed at launching our innovative products on the international stage. Our commitment to advancing global health through cutting-edge biotechnology drives us to extend our reach beyond domestic borders, ensuring that our solutions benefit animals and healthcare providers worldwide.
MILESTONE
2016
Company founded
2016
Company founded
2018
Pipeline Development：Project VJT-101 obtained national clinical trial approval for New Veterinary Drugs
2018
Pipeline Development：Project VJT-101 obtained national clinical trial approval for New Veterinary Drugs
2020
Manufacturing Site： Started Construction
2020
Manufacturing Site： Started Construction
2020
Pipeline Advancement：Project VJT-102 entered clinical trials.
Project VJT-101 completed phase III clinical trials.
Project VJT-101 completed phase III clinical trials.
2020
Pipeline Advancement：Project VJT-102 entered clinical trials.
Project VJT-101 completed phase III clinical trials.
Project VJT-101 completed phase III clinical trials.
2021
Business Promotion：Formed marketing team for nationwide market promotion
2021
Business Promotion：Formed marketing team for nationwide market promotion
2021
Manufacturing Site：Started interior finishing and first phase of GMP plant construction
2021
Manufacturing Site：Started interior finishing and first phase of GMP plant construction
2022
Manufacturing Site：Completed construction
2022
Manufacturing Site：Completed construction
2023
Manufacturing Site：Completed GMP verification
2023
Manufacturing Site：Completed GMP verification
2016
Company founded
2018
Pipeline Development：Project VJT-101 obtained national clinical trial approval for New Veterinary Drugs
2020
Manufacturing Site： Started Construction
2020
Pipeline Advancement：Project VJT-102 entered clinical trials.<br>Project VJT-101 completed phase III clinical trials.
2021
Business Promotion：Formed marketing team for nationwide market promotion
2021
Manufacturing Site：Started interior finishing and first phase of GMP plant construction
2022
Manufacturing Site：Completed construction
2023
Manufacturing Site：Completed GMP verification